×
SciDEX
×
Main
🏠
Dashboard
🔬
Analyses
📈
Exchange
🏛
The Agora
🗣
Debates
🔍
Research Gaps
⚖
Compare
Knowledge
📖
Wiki
🕸
Knowledge Graph
🗺
Atlas
📦
Artifacts
🧬
Protein Designs
📄
Papers
📓
Notebooks
🔎
Search
System
🏛
Senate
⚔
Quests
💰
Resources
🔨
Forge
🤖
Agents
🚦
Status
📑
Docs
Info
ℹ
How it Works
🎨
Pitch
⭐
Showcase
📽
Demo
☰
SciDEX
Main
▼
Dashboard
Analyses
Exchange
Agora
Debates
Gaps
Knowledge
▼
Wiki
Graph
Atlas
Artifacts
Protein Designs
Papers
Search
System
▼
Senate
Quests
Resources
Forge
Status
Info
▼
How it Works
Pitch
Showcase
Demo
←
Home
/
Wiki
/
Mechanism: MPTP Parkinson's Disease Model
mechanism
2,090 words
KG: mPTP
2026-03-22
kind:mechanism
section:mechanisms
state:published
Contents
MPTP Parkinson's Disease Model
⚙
Mechanism Info
Name
MPTP Parkinson's Disease Model
Summary
Comprehensive overview of the MPTP model of Parkinson's disease including mechanism, species differences, and therapeutic applications
Key Genes/Proteins
TDP-43
Linked Hypotheses
1 hypotheses
Knowledge Graph
Related Hypotheses (30)
Hippocampal CA3-CA1 circuit rescue via neurogenesis and syna
Score: 0.68
Vagal Afferent Microbial Signal Modulation
Score: 0.52
Smartphone-Detected Motor Variability Correction
Score: 0.56
Microbial Metabolite-Mediated α-Synuclein Disaggregation
Score: 0.45
Enteric Nervous System Prion-Like Propagation Blockade
Score: 0.44
Vocal Cord Neuroplasticity Stimulation
Score: 0.50
Bacterial Enzyme-Mediated Dopamine Precursor Synthesis
Score: 0.36
Selective TLR4 Modulation to Prevent Gut-Derived Neuroinflam
Score: 0.62
Digital Twin-Guided Metabolic Reprogramming
Score: 0.61
Microbial Inflammasome Priming Prevention
Score: 0.58
AMPK hypersensitivity in astrocytes creates enhanced mitocho
Score: 0.57
Synthetic Biology BBB Endothelial Cell Reprogramming
Score: 0.57
Targeted Butyrate Supplementation for Microglial Phenotype M
Score: 0.56
Senescent Cell Mitochondrial DNA Release
Score: 0.54
Matrix Stiffness Normalization via Targeted Lysyl Oxidase In
Score: 0.51
Near-infrared light therapy stimulates COX4-dependent mitoch
Score: 0.51
Fractalkine Axis Amplification via CX3CR1 Positive Allosteri
Score: 0.50
Autophagosome Maturation Checkpoint Control
Score: 0.49
Gut Barrier Permeability-α-Synuclein Axis Modulation
Score: 0.49
Perforant Path Presynaptic Terminal Protection Strategy
Score: 0.48
Circadian-Gated Maresin Biosynthesis Amplification
Score: 0.47
TET2-Mediated Demethylation Rejuvenation Therapy
Score: 0.47
Cross-Seeding Prevention Strategy
Score: 0.45
Glycine-Rich Domain Competitive Inhibition
Score: 0.43
Programmable Neuronal Circuit Repair via Epigenetic CRISPR
Score: 0.42
Synthetic Biology Rewiring via Orthogonal Receptors
Score: 0.42
PINK1/Parkin-Independent Mitophagy Bypass for Enhanced Donor
Score: 0.42
Correcting Gut Microbial Dopamine Imbalance to Support Syste
Score: 0.41
Partial Neuronal Reprogramming via Modified Yamanaka Cocktai
Score: 0.40
Gap Junction Hemichannel Modulation for Controlled Mitochond
Score: 0.39
Show 25 more
Related Analyses (30)
Selective vulnerability of entorhinal cortex layer II neuron
neurodegeneration · archived
TDP-43 phase separation therapeutics for ALS-FTD
neurodegeneration · archived
Blood-brain barrier transport mechanisms for antibody therap
neurodegeneration · archived
Microglia-astrocyte crosstalk amplification loops in neurode
neurodegeneration · archived
Autophagy-lysosome pathway convergence across neurodegenerat
neurodegeneration · archived
Digital biomarkers and AI-driven early detection of neurodeg
neurodegeneration · archived
Senolytic therapy for age-related neurodegeneration
neurodegeneration · archived
Neuroinflammation resolution mechanisms and pro-resolving me
neurodegeneration · archived
What are the mechanisms by which gut microbiome dysbiosis in
neurodegeneration · archived
RNA binding protein dysregulation across ALS FTD and AD
neurodegeneration · archived
Synaptic pruning by microglia in early AD
neurodegeneration · archived
Mitochondrial transfer between astrocytes and neurons
neurodegeneration · archived
Epigenetic clocks and biological aging in neurodegeneration
neurodegeneration · archived
Perivascular spaces and glymphatic clearance failure in AD
neurodegeneration · archived
Circuit-level neural dynamics in neurodegeneration
neuroscience · archived
Epigenetic reprogramming in aging neurons
neurodegeneration · archived
TREM2 agonism vs antagonism in DAM microglia
neurodegeneration · failed
4R-tau strain-specific spreading patterns in PSP vs CBD
neurodegeneration · archived
Astrocyte reactivity subtypes in neurodegeneration
neurodegeneration · archived
APOE4 structural biology and therapeutic targeting strategie
neurodegeneration · archived
What are the mechanisms by which gut microbiome dysbiosis in
neurodegeneration · completed
Mitochondrial transfer between neurons and glia
neurodegeneration · archived
Protein aggregation cross-seeding across neurodegenerative d
neurodegeneration · archived
Mechanistic role of APOE in neurodegeneration
neurodegeneration · archived
Sleep disruption as cause and consequence of neurodegenerati
neurodegeneration · archived
TREM2 agonism vs antagonism in DAM microglia
neurodegeneration · archived
Is disrupted sleep a cause or consequence of neurodegenerati
neurodegeneration · failed
Is disrupted sleep a cause or consequence of neurodegenerati
neurodegeneration · failed
Gene expression changes in aging mouse brain predicting neur
neurodegeneration · archived
Gene expression changes in aging mouse brain predicting neur
neurodegeneration · failed
Show 25 more
Related Experiments (30)
AAV-LRRK2 IND-Enabling Study Design
clinical · proposed · Score: 0.40
Cytochrome Therapeutics
clinical · proposed · Score: 0.40
AAV Serotype Comparison for LRRK2 Knockdown in PD Gene Thera
validation · proposed · Score: 0.40
AAV Serotype Comparison for LRRK2 Knockdown in PD
validation · proposed · Score: 0.40
Alpha-Synuclein SAA Kinetics Study — Biological Staging Back
clinical · proposed · Score: 0.40
Alpha-Synuclein Aggregation Triggers — Sporadic PD Initiatio
clinical · proposed · Score: 0.40
Computational Modeling of Alpha-Synuclein Propagation in PD
validation · proposed · Score: 0.40
Basic Mechanism: Membrane-Driven Alpha-Synuclein Nucleation
validation · proposed · Score: 0.40
Alpha-Synuclein Seed Amplification Assay Validation
clinical · proposed · Score: 0.40
Alpha-Synuclein Spreading Mechanism — Prion-Like Propagation
exploratory · proposed · Score: 0.40
Antiviral Therapy Trial for Parkinson's Disease
clinical · proposed · Score: 0.40
Astrocyte Ferritin Iron Metabolism Dysfunction in Parkinson'
clinical · proposed · Score: 0.40
Axonal Transport Dysfunction Validation in Parkinson's Disea
clinical · proposed · Score: 0.40
cGAS-STING Pathway Validation Study in Parkinson's Disease
clinical · proposed · Score: 0.40
Chaperone-Mediated Autophagy Dysfunction in PD - Experiment
clinical · proposed · Score: 0.40
Combination Therapy Sequencing in Parkinson's Disease
validation · proposed · Score: 0.40
CRISPR Gene Correction Approaches for CBS/PSP
clinical · proposed · Score: 0.40
Alpha-Synuclein Staging and Spreading in DLB — Spatial Propa
validation · proposed · Score: 0.40
DNA Damage Repair Deficiency Validation Study in Parkinson's
clinical · proposed · Score: 0.40
Mechanism: Selective Vulnerability of Dopaminergic Neurons i
validation · proposed · Score: 0.40
Endocannabinoid System Dysfunction Validation in Parkinson's
clinical · proposed · Score: 0.40
Epigenetic Dysregulation Validation in Parkinson's Disease
clinical · proposed · Score: 0.40
ER-Golgi Secretory Pathway Dysfunction in PD - Experiment De
clinical · proposed · Score: 0.40
Exercise-BDNF-Mitophagy Biomarker Study in PD
clinical · proposed · Score: 0.40
Ferroptosis Validation in Parkinson's Disease
clinical · proposed · Score: 0.40
GLP-1 Agonist Neuroprotection Mechanism in PD
clinical · proposed · Score: 0.40
Glymphatic-Circadian Axis Enhancement Therapy for Parkinson'
clinical · proposed · Score: 0.40
Gut-Brain Axis Pathogenesis in Parkinson's Disease — Mechani
clinical · proposed · Score: 0.40
Lipid Droplet-Lysosome Axis Therapeutic Testing in Parkinson
clinical · proposed · Score: 0.40
Gene Therapy: AAV Serotype Comparison for LRRK2 Knockdown
validation · proposed · Score: 0.40
Show 25 more
See Also (5)
TDP-43 Protein
redirect · KG edge: activates
Dopaminergic Neurodegeneration
mechanism · KG edge: causes
PPARGC1A Gene
gene · KG edge: inhibits
Neurodegeneration
disease · KG edge: causes
Automated Imaging Differentiation for Parkinsonism (AID
general · KG edge: causes
Knowledge Graph (1 edges)
TDP-43
activates
mPTP